Krystal Biotech FY2024 EPS Forecast Raised by William Blair

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Investment analysts at William Blair boosted their FY2024 earnings per share (EPS) estimates for Krystal Biotech in a note issued to investors on Monday, November 4th. William Blair analyst S. Corwin now forecasts that the company will earn $2.96 per share for the year, up from their previous forecast of $2.75. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $2.88 per share. William Blair also issued estimates for Krystal Biotech's Q4 2024 earnings at $1.15 EPS, Q1 2025 earnings at $1.43 EPS, Q3 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.50 EPS and FY2025 earnings at $6.13 EPS.

A number of other equities research analysts have also recently commented on the company. Stifel Nicolaus lifted their target price on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research note on Wednesday, September 11th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, August 5th. Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Evercore ISI upped their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $197.00.

Krystal Biotech Stock Up 5.0 %

Krystal Biotech stock traded up $8.68 during mid-day trading on Wednesday, reaching $183.09. 609,984 shares of the company's stock were exchanged, compared to its average volume of 181,472. The firm has a market capitalization of $5.26 billion, a PE ratio of 103.44 and a beta of 0.82. The business's fifty day simple moving average is $181.39 and its 200 day simple moving average is $180.25. Krystal Biotech has a one year low of $93.95 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the prior year, the company posted ($0.67) earnings per share. The firm's revenue for the quarter was up 879.9% on a year-over-year basis.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of KRYS. Scout Investments Inc. purchased a new position in Krystal Biotech during the first quarter worth about $8,976,000. Sei Investments Co. grew its holdings in shares of Krystal Biotech by 128.3% during the first quarter. Sei Investments Co. now owns 33,752 shares of the company's stock worth $6,005,000 after purchasing an additional 18,968 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Krystal Biotech in the first quarter worth approximately $3,175,000. Price T Rowe Associates Inc. MD lifted its position in Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company's stock valued at $117,189,000 after purchasing an additional 231,255 shares during the last quarter. Finally, Shaker Investments LLC OH bought a new stake in Krystal Biotech during the third quarter valued at approximately $532,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).